Roche Jumps Back Into Huntington’s With Spark/NeuExcell Partnership
Executive Summary
Deal Snapshot: Roche gene therapy subsidiary Spark gets option and will partner with start-up NeuExcell on a Huntington’s gene therapy that researchers say may regenerate functional neurons.
You may also be interested in...
Five (Non-COVID) Clinical Trial Misses Of 2021
The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.
Five (Non-COVID) Clinical Trial Misses Of 2021
The coronavirus pandemic may have dominated the news in 2021, but industry’s more bread and butter R&D activities continued. Here, Scrip takes a look at five of the more notable clinical trial misses of the year that got readers clicking.
Neurocrine Closer To Ingrezza Label Expansion With Huntington’s Chorea Phase III Win
The neuroscience-focused firm plans a 2022 supplemental NDA for Ingrezza following success in the pivotal KINECT-HD study. The biotech needed an R&D success after recent stumbles.